Skip to main content
. Author manuscript; available in PMC: 2012 Sep 18.
Published in final edited form as: Curr Alzheimer Res. 2011 Sep;8(6):666–677. doi: 10.2174/156720511796717195

Figure 1. Tau based therapeutic strategies under development.

Figure 1

Kinase inhibitors targeting GSK3β, MARK and cdk5 or phosphatase activators may reduce pathological tau phosphorylation. Small molecule aggregation inhibitors or immunotherapy may prevent the build-up and spread of toxic tau aggregates. These therapies should reduce the levels of tau oligomers, paired helical filaments and/or neurofibrillary tangles. Additionally, microtubule stabilizing drugs may compensate for loss of tau function by maintaining the integrity of the cytoskeleton. The overall aim of these direct or indirect approaches is to maintain synaptic connections and prevent neuronal loss.